KMT2A and leukemia: A second single-agent trial enrolls patients with MLL-rearranged leukemia either relapse/refractory or newly diagnosed but ineligible for intensive chemotherapy (AMLSG 23-14 Trial; ClinicalTrials.govidentifier: NCT02310243).